DelveInsight’s, “Non-Alcoholic Fatty Liver Disease Pipeline Insight 2024” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Non-Alcoholic Fatty Liver Disease pipeline landscape. It covers the Non Alcoholic Fatty Liver Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non Alcoholic Fatty Liver Disease therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Discover the latest drugs and treatment options in the Non Alcoholic Fatty Liver Disease Pipeline. Dive into DelveInsight’s comprehensive report today! @ Non Alcoholic Fatty Liver Disease Pipeline Outlook

 

Key Takeaways from the Non Alcoholic Fatty Liver Disease Pipeline Report

• July 2024:- Novo Nordisk A/S– The study will last for about 5 years. Participants will have up to 21 clinic visits and 9 phone calls with the clinical staff during the study. Some of the clinic visits may be spread over more than one day. Participants with other chronic liver diseases cannot take part in this study. Women cannot take part in the study if they are pregnant, breast-feeding or plan to become pregnant during the study period.
• July 2024:- Merck Sharp & Dohme LLC– A Phase 2b Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults With Precirrhotic Nonalcoholic Steatohepatitis. The purpose of this study is to learn how well efinopegdutide works compared to placebo in people who have non-alcoholic steatohepatitis (NASH). Researchers will also learn about the safety and benefit of efinopegdutide and how well people tolerate the medicine. The main goal of the study is to compare how many people taking efinopegdutide or placebo stop showing evidence of NASH without liver scarring getting worse.
• July 2024:- Boston Pharmaceuticals- A Phase 2a, Randomized, Blinded, Placebo-controlled Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With a Single Arm Open-label Extension. This is a safety study to evaluate BOS-580 administered subcutaneously with repeated dosing over 12 weeks in Part A or 24 weeks in Part B. Part C is multicenter, open-label safety study in which all participants who completed part B and are interested and met the criteria for part C will be treated with one dose of BOS-580 for 24 weeks.
• DelveInsight’s Non Alcoholic Fatty Liver Disease pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Non Alcoholic Fatty Liver Disease treatment.
• The leading Non Alcoholic Fatty Liver Disease Companies such as Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel, Inventiva Pharma, Galectin Therapeutics, AngioLab, MediciNova, and others.
• Promising Non Alcoholic Fatty Liver Disease Therapies in the various stages of development include Semaglutide, Ursodeoxycholic Acid, INI-822 (A), HEC96719, and others.

 

Stay ahead with the most recent pipeline outlook for Non Alcoholic Fatty Liver Disease. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Non Alcoholic Fatty Liver Disease Approved Drugs

 

Non-Alcoholic Fatty Liver Disease Emerging Drugs

Lanifibranor: Inventiva Pharma

Lanifibranor is an orally-available small molecule that acts to induce anti-fibrotic, anti-inflammatory, and beneficial metabolic changes in the body by activating each of the three PPAR isoforms, known as PPARα, PPARδ, and PPARɣ. Lanifibranor is a PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a well-balanced activation of PPARα and PPARɣ and partial activation of PPARɣ. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Non-Alcoholic Fatty Liver Disease.

ZED 1227: Dr. Falk Pharma GmbH

ZED 1227, is a synthetic peptidomimetic compound designed by Zedira scientists to specifically inhibit the enzymatic activity of human tissue transglutaminase (TG2). Dr. Falk Pharma has acquired the licensing rights to ZED1227 in Europe and several non-European countries and has assumed responsibility for pharmaceutical, preclinical, and clinical development of the new chemical entity towards a pharmaceutical product. By inhibiting TG2 in liver tissue, ZED1227 is expected to improve liver fibrosis in patients with NAFLD. Currently the drug is in Phase II stage of its clinical trial for the treatment of Non-Alcoholic Fatty Liver Disease.

TVB-2640: Sagimet Biosciences

TVB-2640 is an oral, selective, first-in-class fatty acid synthase inhibitor that directly targets the primary drivers of NASH by reducing excess liver fat (steatosis), decreasing inflammation and blunting fibrosis. In addition to the FASCINATE-2 trial, denifanstat is being tested in a Phase III clinical trial for recurrent glioblastoma and a Phase II study for moderate to severe acne. Currently the drug is in Phase II stage of clinical trial for the treatment of Non-Alcoholic Fatty Liver Disease.

ALS-L1023: AngioLab

ALS L1023 is a dried extract of ethyl acetate, prepared by activity-guided fractionation from Melissa leaf (lemon balm). The Angiogenesis Inhibitor ALS-L1023 from Lemon-Balm Leaves Attenuates High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease through Regulating the Visceral Adipose-Tissue Function. Currently the drug is in Phase II stage of its clinical trial for the treatment of Non-Alcoholic Fatty Liver Disease.

AZD9550: AstraZeneca

AZD9550 is a GLP-1R glucagon dual agonist small molecule which is in early development for the treatment of NASH (non-alcoholic steatohepatitis), a type of liver disease that commonly affects overweight and obese patients who have T2DM. Currently the drug is in Phase I/II stage of its clinical trial for the treatment of Non-Alcoholic Fatty Liver Disease.

 

Explore groundbreaking therapies and clinical trials in the Non Alcoholic Fatty Liver Disease Pipeline. Access DelveInsight’s detailed report now! @ Non Alcoholic Fatty Liver Disease Treatment Drugs

 

Non-Alcoholic Fatty Liver Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

 

Non Alcoholic Fatty Liver Disease Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

 

Unveil the future of Non Alcoholic Fatty Liver Disease Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Non Alcoholic Fatty Liver Disease Market Drivers and Barriers

 

Scope of the Non Alcoholic Fatty Liver Disease Pipeline Report

• Coverage- Global
• Non Alcoholic Fatty Liver Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Non Alcoholic Fatty Liver Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Non Alcoholic Fatty Liver Disease Companies- Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel, Inventiva Pharma, Galectin Therapeutics, AngioLab, MediciNova, and others.
• Non Alcoholic Fatty Liver Disease Therapies- Semaglutide, Ursodeoxycholic Acid, INI-822 (A), HEC96719, and others.

 

Get the latest on Non Alcoholic Fatty Liver Disease Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Non Alcoholic Fatty Liver Disease Companies, Key Products and Unmet Needs

 

Table of Content

1. Introduction
2. Executive Summary
3. Non-Alcoholic Fatty Liver Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Non-Alcoholic Fatty Liver Disease – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name: Company name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. ZED 1227: Dr. Falk Pharma GmbH
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug name: Company name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name : Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Non-Alcoholic Fatty Liver Disease Key Companies
21. Non-Alcoholic Fatty Liver Disease Key Products
22. Non-Alcoholic Fatty Liver Disease – Unmet Needs
23. Non-Alcoholic Fatty Liver Disease – Market Drivers and Barriers
24. Non-Alcoholic Fatty Liver Disease – Future Perspectives and Conclusion
25. Non-Alcoholic Fatty Liver Disease Analyst Views
26. Non-Alcoholic Fatty Liver Disease Key Companies
27. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09193216187
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/